{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:02Z","timestamp":1792601402468,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug toxicity does not affect patients equally; the toxicity may only exert in patients who possess certain attributes of susceptibility to specific drug properties (i.e., drug-host interaction). This concept is crucial for personalized drug safety but remains under-studied, primarily due to methodological challenges and limited data availability. By monitoring a large volume of adverse event reports in the postmarket stage, spontaneous adverse event reporting systems provide an unparalleled resource of information for adverse events and could be utilized to explore risk disparities of specific adverse events by age, sex, and other host factors. However, well-formulated statistical methods to formally address such risk disparities are currently lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this paper, we present a statistical framework to explore spontaneous adverse event reporting databases for drug-host interactions and detect risk disparities in adverse drug events by various host factors, adapting methods for safety signal detection. We proposed four different methods, including likelihood ratio test, normal approximation test, and two tests using subgroup ratios. We applied our proposed methods to simulated data and Food and Drug Administration (FDA) Adverse Event Reporting Systems (FAERS) and explored sex-\/age-disparities in reported liver events associated with specific drug classes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The simulation result demonstrates that two tests (likelihood ratio, normal approximation) can detect disparities in adverse drug events associated with host factors while controlling the family wise error rate. Application to real data on drug liver toxicity shows that the proposed method can be used to detect drugs with unusually high level of disparity regarding a host factor (sex or age) for liver toxicity or to determine whether an adverse event demonstrates a significant unbalance regarding the host factor relative to other events for the drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Though spontaneous adverse event reporting databases require careful data processing and inference, the sheer size of the databases with diverse data from different countries provides unique resources for exploring various questions for drug safety that are otherwise impossible to address. Our proposed methods can be used to facilitate future investigation on drug-host interactions in drug toxicity using a large number of reported adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12874-023-01885-w","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:03:02Z","timestamp":1679911382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhiyuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"1885_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"1885_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"1885_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1198\/jasa.2011.ap10243","volume":"106","author":"L Huang","year":"2011","unstructured":"Huang L, Zalkikar J, Tiwari RC. A likelihood ratio test based method for signal detection with application to FDA\u2019s drug safety data. J Am Stat Assoc. 2011;106:1230\u201341.","journal-title":"J Am Stat Assoc."},{"key":"1885_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10543406.2013.736810","volume":"23","author":"L Huang","year":"2013","unstructured":"Huang L, Zalkikar J, Tiwari RC. Likelihood ratio test-based method for signal detection in drug classes using FDA\u2019s AERS database. J Biopharm Stat. 2013;23:178\u2013200.","journal-title":"J Biopharm Stat."},{"key":"1885_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang L. A review of statistical methods for safety surveillance. Ther Innov Regul Sci. 2014;48:98\u2013108.","journal-title":"Ther Innov Regul Sci."},{"key":"1885_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1080\/10543406.2017.1295250","volume":"27","author":"K Nam","year":"2017","unstructured":"Nam K, Henderson NC, Rohan P, Woo EJ, Russek-Cohen E. Logistic regression likelihood ratio test analysis for detecting signals of adverse events in post-market safety surveillance. J Biopharm Stat. 2017;27:990\u20131008.","journal-title":"J Biopharm Stat."},{"key":"1885_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10543406.2020.1783284","volume":"31","author":"Z Xu","year":"2021","unstructured":"Xu Z, Xu J, Yao Z, Huang L, Jung M, Tiwari R. Evaluating medical device adverse event signals using a likelihood ratio test method. J Biopharm Stat. 2021;31:37\u201346.","journal-title":"J Biopharm Stat."},{"key":"1885_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/0962280216646678","volume":"27","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Yi M, Tiwari RC. Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA\u2019s adverse event reporting system database. Stat Methods Med Res. 2018;27:876\u201390.","journal-title":"Stat Methods Med Res."},{"key":"1885_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol."},{"key":"1885_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u201390.","journal-title":"Am Stat."},{"key":"1885_CR11","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Nor\u00e9n","year":"2006","unstructured":"Nor\u00e9n GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25:3740\u201357.","journal-title":"Stat Med."},{"key":"1885_CR12","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1002\/sim.6510","volume":"34","author":"N Hu","year":"2015","unstructured":"Hu N, Huang L, Tiwari RC. Signal detection in FDA AERS database using dirichlet process. Stat Med. 2015;34:2725\u201342.","journal-title":"Stat Med."},{"key":"1885_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/sam.10078","volume":"3","author":"O Caster","year":"2010","unstructured":"Caster O, Nor\u00e9n GN, Madigan D, Bate A. Large scale regression based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min ASA Data Sci J. 2010;3:197\u2013208.","journal-title":"Stat Anal Data Min ASA Data Sci J."},{"key":"1885_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Patrick PY, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125\u201331.","journal-title":"Sci Transl Med."},{"key":"1885_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","volume":"43","author":"L Sandberg","year":"2020","unstructured":"Sandberg L, Taavola H, Aoki Y, Chandler R, Nor\u00e9n GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43:999\u20131009.","journal-title":"Drug Saf."},{"key":"1885_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1145\/2110363.2110395","volume-title":"Proceedings of the 2nd ACM SIGHIT international health informatics symposium","author":"J Hopstadius","year":"2012","unstructured":"Hopstadius J, Nor\u00e9n GN. Robust discovery of local patterns: subsets and stratification in adverse drug reaction surveillance. In: Yang Y, editor. Proceedings of the 2nd ACM SIGHIT international health informatics symposium. New York: Association for Computing Machinery; 2012. p. 265\u201374."},{"key":"1885_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.yrtph.2018.01.018","volume":"94","author":"N George","year":"2018","unstructured":"George N, Chen M, Yuen N, Hunt CM, Suzuki A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul Toxicol Pharmacology. 2018;94:101\u20137.","journal-title":"Regul Toxicol Pharmacology."},{"key":"1885_CR18","doi-asserted-by":"publisher","first-page":"e0122786","DOI":"10.1371\/journal.pone.0122786","volume":"10","author":"M Mennecozzi","year":"2015","unstructured":"Mennecozzi M, Landesmann B, Palosaari T, Harris G, Whelan M. Sex differences in liver toxicity-do female and male human primary hepatocytes react differently to toxicants in vitro? PloS ONE. 2015;10:e0122786.","journal-title":"PloS ONE."},{"key":"1885_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503\u201314.","journal-title":"J Hepatol."},{"key":"1885_CR20","volume-title":"Statistical Inference","author":"G Casella","year":"2011","unstructured":"Casella G, Berger RL. Statistical Inference. 2nd ed. Boston: Cengage Learning; 2011.","edition":"2"},{"key":"1885_CR21","volume-title":"Multiple Comparisons Using R","author":"F Bretz","year":"2011","unstructured":"Bretz F, Hothorn T, Westfall P. Multiple Comparisons Using R. Boca Raton: CRC Press; 2011."},{"key":"1885_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B."},{"key":"1885_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:1\u201311.","journal-title":"Sci Data."},{"key":"1885_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, et al. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseTM. Regul Toxicol Pharmacol. 2015;72:481\u201390.","journal-title":"Regul Toxicol Pharmacol."},{"key":"1885_CR25","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.3748\/wjg.v16.i45.5651","volume":"16","author":"F Bessone","year":"2010","unstructured":"Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol WJG. 2010;16:5651\u201361.","journal-title":"World J Gastroenterol WJG."},{"key":"1885_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","volume":"45","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Isgr\u00f3 V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, et al. Post-marketing surveillance of CAR-T-cell therapies: Analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45:891\u2013908.","journal-title":"Drug Saf."},{"key":"1885_CR27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.cgh.2017.11.042","volume":"16","author":"JB Rubin","year":"2018","unstructured":"Rubin JB, Hameed B, Gottfried M, Lee WM, Sarkar M, Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure is more common and more severe in women. Clin Gastroenterol Hepatol. 2018;16:936\u201346.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1885_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.etp.2012.05.004","volume":"65","author":"I Campesi","year":"2013","unstructured":"Campesi I, Galistu A, Carru C, Franconi F, Fois M, Zinellu A. Glutamyl cycle in the rat liver appears to be sex-gender specific. Exp Toxicol Pathol. 2013;65:585\u20139.","journal-title":"Exp Toxicol Pathol."},{"key":"1885_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1590\/S0100-879X1998000900002","volume":"31","author":"MAC Benedito","year":"1998","unstructured":"Benedito MAC. Gender differences in the activities of aspirin-esterases in rat tissues. Braz J Med Biol Res. 1998;31:1113\u20138.","journal-title":"Braz J Med Biol Res."},{"key":"1885_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-60053-y","volume":"10","author":"S Tiwari","year":"2020","unstructured":"Tiwari S, Mishra M, Salemi MR, Phinney BS, Newens JL, Gomes A. Gender-specific changes in energy metabolism and protein degradation as major pathways affected in livers of mice treated with ibuprofen. Sci Rep. 2020;10:1\u201317.","journal-title":"Sci Rep."},{"key":"1885_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2125.2003.01753.x","volume":"55","author":"I Meineke","year":"2003","unstructured":"Meineke I, T\u00fcrck D. Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. British J Clin Pharmacol. 2003;55:32\u20138.","journal-title":"British J Clin Pharmacol."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-01885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-023-01885-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-01885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T02:55:52Z","timestamp":1729133752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-023-01885-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1186\/s12874-023-01885-w","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at FDA National Center for Toxicological Research provided approval for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}